Alison Fujii is a Field Application Scientist at Oxford Nanoimaging, Inc. (ONI). She specializes in extracellular vesicle research using super-resolution microscopy on the ONI Nanoimager. Alison has worked with flow cytometry in cancer immunology research and collaborates with academic labs and bio/pharma industries to advance microscopy techniques for exploring cellular processes at the nanoscale.

Daniel T. Chiu is currently the A. Bruce Montgomery Professor Chemistry, Endowed Professor of Analytical Chemistry, and Professor of Bioengineering at the University of Washington. He is a member of the University of Washington’s Center for Nanotechnology, Neurobiology and Behavior Program, and the Cancer Consortium of the Fred Hutchinson Cancer Research Center. He has authored more than 180 publications and is the inventor on over 40 issued patents. Dr. Chiu obtained a B.A. in neurobiology and a B.S. in chemistry at the University of California, Berkeley in 1993, and a Ph.D. in chemistry from Stanford University in 1998.

Dino Di Carlo received his B.S. in Bioengineering from the University of California, Berkeley in 2002 and received a Ph.D. in Bioengineering from the University of California, Berkeley and San Francisco in 2006. From 2006-2008 he conducted postdoctoral studies in the Center for Engineering in Medicine at Harvard Medical School. He has been on the faculty in the Department of Bioengineering at UCLA since 2008 and now as Professor of Bioengineering and Mechanical Engineering serves as the Chair of the Department and as the director of the Cancer Nanotechnology Program in the Jonsson Comprehensive Cancer Center. His research pioneered the use of inertial fluid dynamic effects for the control, separation, and analysis of cells in microfluidic devices. His recent work extends into numerous other fields of biomedicine and biotechnology including directed evolution, cell analysis for rapid diagnostics, new amplified molecular assays, next generation biomaterials, and phenotypic drug screening. He has also been a leader in technology entrepreneurship: He co-founded and currently serves on the board of directors of five companies that are commercializing UCLA intellectual property developed in his lab (CytoVale, Vortex Biosciences, Tempo Therapeutics, Forcyte Biotechnologies and Ferrologix). Among other honors he received the Presidential Early Career Award for Scientists and Engineers (PECASE) and was elected a Fellow of the American Institute for Medical and Biological Engineering in 2016, was elected a Fellow of the Royal Society of Chemistry (FRSC) in 2014, was awarded the National Science Foundation (NSF) Faculty Early Career Development award and the U.S. Office of Naval Research (ONR) Young Investigator Award, the Packard Fellowship and Defense Advanced Research Projects Agency (DARPA) Young Faculty Award, and received the National Institutes of Health (NIH) Director’s New Innovator Award and Coulter Translational Research Award.

Eric Diebold is the Worldwide Vice President of Research and Development for BD Biosciences, where he leads all aspects of product and technology development for the Biosciences business unit within Becton Dickinson and Co., one of the world’s largest medical technology companies. Eric has been with BD Biosciences for the past 7 years, where he has served in roles of increasing responsibility within the R&D function. Prior to BD, Eric was the CEO and Founder of Omega Biosystems Incorporated, which was acquired by BD in 2017. Eric received his BS in Electrical Engineering and Physics from Duke University, and his PhD in Applied Physics from Harvard University. He lives in Menlo Park, CA with his wife and three sons.

Dr. Cooksey is a Project Leader in the Microsystems and Nanotechnology Division at the National Institute of Standards and Technology (NIST). His lab develops microfluidic platforms with integrated optical structures to measure fluids, particles, and cells with high precision. His team’s optofluidic flow meter is the most accurate flow metrology platform in the world, and it has a response time on the order of 0.1 s at 1 nL/min. Dr. Cooksey also leads a microfluidic cytometry project that uses multiple interrogation regions to extract first ever per-object uncertainty quantification and measurement of dynamics in flow. This technology was awarded a Gold Medal and the 2023 Ron Brown Excellence in Innovation Award by the U.S. Department of Commerce.

Dr Fraikin developed Spectradyne’s initial Microfluidic Resistive Pulse Sensing technology as part of his PhD thesis work at UC Santa Barbara in the research group of Dr. Andrew Cleland. After graduating he received postdoctoral training in cancer cell biology and biochemistry and worked in industry developing microfluidics-based molecular diagnostics. Dr. Fraikin is a co-founder of Spectradyne and now serves as the company’s CEO.

Past President of ISAC. Inventor of Cellarcus’ vesicle analysis technologies. Internationally recognized expert in cytometry and vesicle analysis.

Dr. Joe de Rutte is the Co-Founder and CEO of Partillion Bioscience, a venture-backed startup that is commercializing the Nanovial technology he pioneered during his PhD at UCLA. This technology utilizes hydrogel microparticles to enable researchers to perform microfluidic assays without the need for new, complex instruments. The impact of his work has been recognized by leaders in the field, earning him the top Innovation Award at SLAS 2020 and the New Product Award in 2022. Since its inception, Dr. de Rutte has led Partillion, successfully raising venture capital funding and launching its first commercial products. These developments address a growing need for functional analysis of cells, showcasing the significant contributions of Dr. de Rutte and his team to the scientific community.

Dr Pulliam received her BA degree from Northwestern University, her MS in Microbiology at California State University at Long Beach and her PhD in Experimental Pathology at the University of California, San Francisco (UCSF). She is a Professor of Laboratory Medicine and Medicine at UCSF and Director of Microbiology at the San Francisco VA Health Care Center. She was the Director of Research at the SF VA, the largest VA research center in the US, for 7 years. She is a founding member and past President of the International Society for Neurovirology (ISNV) as well as the Women in Neuroscience awardee and recipient of the ISNV Pioneer Award. She serves on the Board of Directors of ISNV and the Editorial Boards of several journals. She has also received awards from AmFar, the Northern California Institute for Research and Education and Drexel University Prize in Neurovirology.

Dr. Malgorzata (Maggie) A. Witek is an Associate Research Professor at KU, Lawrence. Her research is focused on microfluidic-based isolation and solid-phase extractions of liquid biopsy markers, including circulating tumor cells, extracellular vesicles, and cell free DNA for stroke and cancer disease management. She shares her research efforts between the University of Kansas in the NIH/NIBIB funded Center of BioModular Multiscale Systems for Precision Medicine and the COBRE funded Kansas Institute for Precision Medicine at the University of Kansas Medical Center (KUMC). Maggie co-directs the Liquid Biopsy Core at KUMC campus.

Michael Graner received his PhD in Biochemistry from the University of Illinois followed by post-doctoral and research faculty work at the University of Arizona, shifting gears from the Drosophila extracellular matrix to cancer immunotherapy. He then took at faculty position at Duke University’s Tisch Brain Tumor Center, followed by his current position as Professor in Neurosurgery at the University of Colorado Denver (Anschutz Medical Campus). He is also a member of the University of Colorado Cancer Center, the Colorado Clinical and Translational Sciences Institute, the MAVRC Program, and holds a Visiting Professorship Appointment at the Shenzhen Third People’s Hospital (China) and an adjunct faculty appointment at Colorado State University. Graner has a long-standing interest in cell stress responses, which led to cancer vaccine development (including one in clinical trials), which somehow led to the world of extracellular vesicles (EVs). His lab currently concentrates on signaling mechanisms involving EVs, in particular the transfer of stressed phenotypes from stressed tumor cells to unstressed ones via EVs.

Prof. Soper is a Foundation Distinguished Professor in Chemistry, Bioengineering, and Mechanical Engineering at the University of Kansas. At KUMC, Prof. Soper holds an adjunct appointment in the Cancer Biology Department and is a member of the KU Cancer Center.

Prof. Soper has secured extramural funding totaling >$135M, has published over 245 peer-reviewed manuscripts (h index = 70; >18,000 citations); 31 book chapters and 91 peer-reviewed conference proceeding papers, and is the author of 20 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of liquid biopsy markers. Soper recently founded a second company, Sunflower Genomics, which is seeking to market a new DNA/RNA single-molecule sequencing platform. His list of awards includes Ralph Adams Award in Bioanalytical Chemistry, Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 60 PhDs and 7 MS degrees to students under his mentorship. He currently heads a group of 20 researchers.

Sven Kreutel studied biology at the University of Hohenheim in Stuttgart, Germany. After his graduation in biology, he received his PhD in microbiology and protein biochemistry at the University of Hohenheim under Prof. Dr. Andreas Kuhn and Dr. Dorothee Kiefer working on the light sensing and signal transduction in photosynthetic bacteria. Since then he worked in different sales and sales manager positions within the life science industry from clinical research over biology to nanoparticle sciences. In 2021 he was appointed as CEO of the American subsidiary of Particle Metrix.

Dr. Morgan is a Professor of Pathology and Biomedical Engineering at Oregon Health & Science University (OHSU) in Portland, Oregon, USA. He has been an NIH-funded investigator since 2012 and he has worked with BD Biosciences since 2016 to develop, validate, and begin research trials using nanoscale high resolution flow cytometry to image, count, and isolate extracellular vesicles (EVs). Dr. Morgan is the leader of the EV research group at the Center for Developmental Health at OHSU. He is also the leader of the flow cytometry EV group at the Knight Cancer Institute to test its potential as a diagnostic platform for early cancer detection.

Yuhwa Lo received his PhD in electrical engineering from UC Berkeley. He has been a professor of University of California, San Diego since 1999. He is also the director of the UCSD Nano3 (Nanoscience, Nanoengineering, Nanomedicine) Facility. His research interests include microfluidics, lab on a chip, biosensors, biomedical instrument, biophotonics, nanophotonic and optoelectronic devices. He has around 400 publications and been award 31 patents. He is a fellow of the IEEE and the Optical Society of America.